Hall Render

MAY 9, 2023

Notably, the Temporary Rule, which can be accessed here , extends the COVID-19 PHE telemedicine flexibilities (hereinafter, “telemedicine flexibilities”) for six months following the end of the PHE (through November 11, 2023). Still, telemedicine providers should closely monitor for the DEA’s final rules, once they are issued.

COVID-19 40

COVID-19 Telemedicine Health Services Administration Public Health 40

Healthcare Law Blog

OCTOBER 17, 2023

Under the Second Temporary Rule, practitioners may continue to prescribe schedule II-V controlled medications via telemedicine for new and existing patients without conducting a prior in-person medical evaluation through 2024. Providers with questions or seeking counsel can contact any member of our Healthcare Team for assistance.

Telemedicine 52

Telemedicine COVID-19 Health Services Administration Public Health 52

Health Law Advisor

MARCH 7, 2023

The proposed rules are more restrictive than the DEA emergency waivers under which providers conducted telemedicine prescribing for the last three years, but are less restrictive in comparison to the pre-PHE regulations applicable to telemedicine prescribing of controlled substances under the federal Controlled Substances Act (“CSA”).

Telemedicine 52

Telemedicine COVID-19 FDA Compliance 52

Bill of Health

NOVEMBER 15, 2023

The nation’s experience with COVID-19 demonstrated the need for increased telemedicine options for the treatment of substance use, especially in suburban and rural areas where health provider closures may severely limit access to care. Code § 1701 et seq.

Governance 167

Governance Public Health Telemedicine Medicaid 167